Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and EDT in Fibrolamellar HCC
NCT01642186Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2012
- Primary completion
- Jul 2021
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, letrozole, leuprolide in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2012; status: completed.
02
Drugs
everolimusletrozoleleuprolide
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT01642186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642186.